Загрузка...
Phase II study of sunitinib in men with advanced prostate cancer
Background: This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC). Methods: Men with no prior chemotherapy (group A) and men with docetaxel (Taxotere)-resistant prostate cancer (group B) were...
Сохранить в:
| Главные авторы: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2009
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2674960/ https://ncbi.nlm.nih.gov/pubmed/19403935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdp111 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|